# Merck & Cie – FDA 483, Nov 2, 2018

Source: https://www.keypedia.com/records/483/merck-cie/4dc6a2a1-e793-4f85-945b-f6bb9c135cac

> FDA 483 for Merck & Cie on November 02, 2018. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Merck & Cie
- Inspection Date: 2018-11-02
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: During an inspection of Merck & Cie, an API manufacturer in Schaffhausen, Switzerland, the FDA observed significant deficiencies in the control of computer and laboratory systems. Specifically, laboratory personnel were assigned administrator roles allowing data manipulation, and the chromatographic software lacked essential audit trail capabilities. These findings indicate a lack of appropriate controls over electronic raw data and potential data integrity issues.

## Related Officers

- [Consumer Safety Officer - Dedicated Foreign Drug Cadre](https://www.keypedia.com/people/tamil-arasu/94efc491-7d9f-4221-a1ee-69a925acb1c3)
- [Managing Director](https://www.keypedia.com/people/rudolf-moser/6afd6325-992a-4e3d-896c-9c0b744322d7)

Company: https://www.keypedia.com/companies/merck-cie/7a318238-e1c9-4962-94fe-53359569a739

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1
